Article Information
History
- January 4, 2022.
Article Versions
- Version 1 (December 5, 2021 - 09:07).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- 1Department of Internal Medicine, Division of Infectious Diseases, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
- 2Medigen Vaccine Biologics Corporation, Taipei, Taiwan
- 3Research Centre for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan
- 4Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei City, Taiwan
- ↵*Co-corresponding authors: Szu-Min Hsieh: hsmaids{at}hotmail.com; Chia En Lien: allenlien{at}medigenvac.com
Posted January 04, 2022.
The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: An extension to an open-label, dose-escalation, and non-randomized phase 1 study
